Home|Journals|Articles by Year|Audio Abstracts
 

Original Article



Acute Kidney Injury Following COVID-19 and Risk factors for Progression to Chronic Kidney Disease

enver yüksel, derya deniz altıntaş.




Abstract
Cited by 0 Articles

Background: Acute kidney injury (AKI) is one of the frequent complications of COVID-19 infection. The predictors of progressive kidney disease for patients with COVID-19- associated AKI (COV-AKI) are unclear. In our study, we aimed to demonstrate the risk factors of non-recovery of COV-AKI.
Method: COV-AKI developed in 901 of 3337 patients treated in our hospital for COVID-19 between April 1, 2020 and November 30, 2020. 331 of 901 patients with COV-AKI died at the hospital. Of these patients, 459 patients who met the inclusion criteria were included in the study, while 111 patients were excluded. At 3 months post-AKI, 399 of 459 cases (Group 1) recovered from AKI, and 60 (Group 2) did not.
Results: The median age of the patients included in the study was 68 (59-76), and 44.9% (206) of them were women. Thirty-five of 60 patients in Group 2 developed de novo chronic kidney disease while 25 patients had a history of chronic kidney disease (CKD) and experienced a disease progression. We found that patients with low serum albumin levels (hypoalbuminemia) at admission (P

Key words: Keywords: Acute kidney injury, Chronic Kidney Disease, COVID-19, hypoalbuminemia.






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.